前瞻性随机试验中,血管腔内动脉瘤修复的经皮入路比股动脉切开显著更便宜
这项前瞻性随机单中心试验纳入50例腹主动脉瘤腔内修复患者,每例一侧腹股沟随机经皮入路、另一侧手术切开。按方案完成的44例中,经皮入路耗时更短、总费用更低、伤口并发症更少、术后疼痛更轻;意向性分析中经皮入路仍耗时更短,但两种方法费用无显著差异。
要点
- 经皮入路平均耗时11.5±3.4分钟,切开入路24.8±12.1分钟(P<.001)。
- 经皮入路总费用€559.65±€112.69,切开入路€674.85±€289.55(P=.016)。
- 切开入路发生8例并发症(6例患者),经皮入路无并发症(P=.02)。
核心结论
- 数据证实经皮入路的微创优势,并显示尽管闭合装置有额外费用,经皮入路仍具成本效益。
- 即使计入经皮入路失败,经皮入路费用仍未超过切开入路。
- 考虑到术后疼痛和伤口并发症减少,该技术在合适患者中值得考虑。
研究设计与样本
- 前瞻性随机单中心试验,纳入50例接受血管腔内动脉瘤修复的患者,每例一侧腹股沟随机经皮入路、另一侧手术切开入路。
- 主要终点为入路耗时和费用,次要终点为伤口并发症和术后疼痛水平。
- 44例按方案完成手术;意向性分析纳入50例。
主要发现
- 按方案分析中,经皮入路平均耗时11.5±3.4分钟 vs 切开入路24.8±12.1分钟(P<.001)。
- 按方案分析中,经皮入路总费用€559.65±€112.69 vs 切开入路€674.85±€289.55(P=.016)。
- 切开入路发生8例并发症(6例患者),经皮入路无并发症(P=.02)。
- 术后第1天和第5天,经皮入路侧腹股沟疼痛显著更轻(P<.001)。
- 意向性分析(N=50)中,经皮入路平均总耗时14.65±10.20分钟 vs 切开入路25.12±11.77分钟(P<.001),费用€651.29±€313.49 vs €625.53±€238.29(P=.65)。
临床怎么用
- 作者认为,考虑到术后疼痛和伤口并发症减少,该技术在合适患者中值得考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Because of its minimally invasive nature, percutaneous femoral access for endovascular aneurysm repair (pEVAR) is currently undergoing rapid popularization. Compared with surgical cutdown for femoral access (cEVAR), it offers the advantage of faster recovery after surgery as well as a reduction in wound complications. Despite proposed advantages, the method is largely considered uneconomical because of its reliance on costly closure devices. METHODS: There were 50 patients undergoing EVAR who were enrolled in this randomized prospective single-center trial. Each patient randomly received percutaneous access in one groin and surgical access in the other. The primary end points were access duration and cost. Secondary end points were wound complications and the postoperative pain levels. RESULTS: Surgery was performed per protocol in 44 patients. Mean access times for pEVAR and cEVAR were 11.5 ± 3.4 minutes and 24.8 ± 12.1 minutes (P < .001), respectively. Total access costs were €559.65 ± €112.69 for pEVAR and €674.85 ± €289.55 for cEVAR (P = .016). Eight complications in six patients were attributed to cutdown, none to pEVAR (P = .02). The percutaneously accessed groin was significantly less painful at day 1 and day 5 after surgery (P < .001). An intention-to-treat analysis (N = 50 patients) included six cases of pEVAR conversion due to technical failure in three patients (6%) and change of the operative strategy in another three patients (eg, aortouni-iliac stent graft followed by crossover bypass). The intention-to-treat analysis showed shorter mean overall access time for pEVAR (pEVAR, 14.65 ± 10.20 minutes; cEVAR, 25.12 ± 11.77 minutes; P < .001) and no cost difference between the two methods (pEVAR, €651.29 ± €313.49; cEVAR, €625.53 ± €238.29; P = .65). CONCLUSIONS: Our data confirm proposed potential benefits attributable to the minimally invasive nature of pEVAR while demonstrating cost-effectiveness despite the additional cost of closure devices. Taking into account pEVAR failures still does not increase pEVAR costs over cEVAR. Further considering reduced postoperative pain and wound complications, the technique deserves consideration in suitable patients.
引用
- Uhlmann ME, Walter C, Taher F, et al. Successful percutaneous access for endovascular aneurysm repair is significantly cheaper than femoral cutdown in a prospective randomized trial. J Vasc Surg. 2018. PMID: 29526378. doi:10.1016/j.jvs.2017.12.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。